FA
FPRX

Fortis Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Fortis Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-250
Closed -$5K – 329
2017
Q4 		$5K Sell
250
-2,378
-90% -$76.5K ﹤0.01% 265
2017
Q3 		$108K Buy
+2,628
New +$82.5K 0.07% 112

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fortis Advisors's FPRX Position: Q1 2018 in Review

Fortis Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 250 shares — an estimated $5K sold.

Fortis Advisors first reported a position in FPRX in Q3 2017 and held it in 2 quarters. The position peaked at $108K in Q3 2017. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

  • Fortis Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Fortis Advisors sold 250 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $5K.
  • Fortis Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Fortis Advisors's Five Prime Therapeutics, Inc. position peaked at $108K in Q3 2017.
  • 128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on Fortis Advisors's 13F filing for Q1 2018, filed 11 May 2018.